Purpose:The aim of this project was to characterize the incidence of men’s health disorders, specifically focusing on the incidence of erectile dysfunction (ED) and testosterone deficiency (TD) in a large, nationwide study of testicular cancer (TC) …
Don’t miss this unique opportunity to introduce your clinical trials to the global urologic community!
Among those with Signature II tumors, overall survival was improved among those who received nivolumab compared with those who received everolimus.
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t…
“There’s state advocacy work groups and other public policy work groups where folks can remain involved and keep pushing to improve the delivery of health…
“This is another therapeutic that adds to UroGen as a potential treatment that could be used to preserve kidneys while treating low grade upper tract…
Can’t sign in? Forgot your password? If the address matches an existin g account you will receive an email with instructions to reset your password.…
The BLA for TLX250-CDx was initially submitted to the FDA in June 2024.
The evidence in the field of diagnosis, staging, and treatment of localised prostate cancer (PCa) is evolving rapidly. The 2024 European Association of Urology (EAU)-European…
Today’s podcast episode is part of the “Voices” series and is brought to you by the Diversity, Equity & Inclusion Committee. Join Dr. Denise Asafu-Adjei,…
Catch up on all the notable drug and device approvals in urology over the past year.
